DOCSLIB.ORG

(TPZ) Prodrugs for the Management of Hypoxic Solid Tumors by Sindhuja

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(TPZ) Prodrugs for the Management of Hypoxic Solid Tumors by Sindhuja Evaluation of bioreductively-activated Tirapazamine (TPZ) prodrugs for the management of hypoxic solid tumors by Sindhuja Pattabhi Raman A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Cancer Sciences Department of Oncology University of Alberta © Sindhuja Pattabhi Raman, 2019 Abstract Solid tumors often have large areas with low levels of oxygen (termed hypoxic regions), which are associated with poor prognosis and treatment response. Tirapazamine (TPZ), a hypoxia targeting anticancer drug, started as a promising candidate to deal with this issue. However, it was withdrawn from the clinic due to severe neurotoxic side effects and poor target delivery. Hypoxic cells overexpress glucose transporters (GLUT) - a key feature during hypoxic tumor progression. Our project aims at conjugating TPZ with glucose to exploit the upregulated GLUTs for its delivery, and thereby facilitate the therapeutic management of hypoxic tumors. We hypothesized that glucose-conjugated TPZ (G6-TPZ) would be selectively recruited to these receptors, facilitating its entrapment in poorly oxygenated cells only, with minimal damage to their oxygenated counterparts. However, our results reveal that the addition of the glucose moiety to TPZ was counterproductive since G6-TPZ displayed selective hypoxic cytotoxicity only at very high concentrations of the compound. We speculate that the reduced cytotoxicity of G6-TPZ might be due to the fact that the compound was not taken up by the cells. In order to monitor the cellular uptake of TPZ, we developed a click chemistry-based approach by incorporating an azido (N3) group to our parent compound (N3-TPZ). We observed that the azido-conjugated TPZ was highly hypoxia selective and the compound successfully tracks cellular hypoxia. Using a similar methodology, we went on to isolate and identify the proteins that are modified by N3-TPZ under hypoxia in order to obtain a better understanding of the potential underlying molecular mechanism of TPZ cytotoxicity. In addition, we exploited the property of monitoring TPZ uptake by N3-TPZ to study the uptake and localization of G6-TPZ by synthesizing a new derivative of TPZ, which incorporated both glucose and azido moieties. Overall, we carried out the above specified structural modifications on TPZ as an attempt to overcome the limitations of TPZ therapy. ii Acknowledgements I owe sincere gratitude to my co-supervisors, Dr. Michael Weinfeld and Dr. Piyush Kumar for their constant support and motivation without which this dissertation would not be possible. I wish to thank them for providing me the opportunity to work in their team and providing mentorship, motivation, invaluable guidance and encouragement throughout the project, which set the direction for my research. I would like to sincerely thank Dr. Lynne Postovit for kindly letting me work in her laboratory for a year and supervising me in my earlier days. I am indebted to her for all her constructive suggestions and advice in various meetings throughout the research. I also would like to extend my thanks to her lab members who were kind and friendly towards me. My sincere thanks to Dr. Richard Fahlman for letting us perform mass spectrometry in his laboratory and am deeply grateful for his kind assistance and valuable suggestions with the data analysis. I also would like to extend my gratitude to Jack Moore who helped us with the proteomics. My special thanks to Dr. Hassan Elsaidi for designing and synthesizing all the drugs that have been used in this project. Without his effort, it would have been impossible to carry out this work smoothly. I also owe a lot to Faisal Bin Rashed, who is a very good friend and has been a great constant support throughout the entire project. His friendly talks, continual encouragement, valuable discussions and timely help made this journey considerably easier. Most importantly, I would like to thank all the CRIO group members for their warmth of kindness and interesting discussions in our monthly meetings which have been very beneficial. I am delighted and indebted to Dr. Dawn McDonald and Xiao-Hong Yang who constantly helped iii and guided me with their technical expertise. I heartily thank Mesfin Fanta and Xiaoyan Yang who were always welcoming, amicable and willing to help. Furthermore, I am immensely pleased to thank my best friends in the lab Zahra Shire, Diana Diaz, Bingcheng Jiang and Wisdom Kate who made my research experience cheerful and uplifting by providing a great positive working environment. In addition, I would like to thank Dr. Feridoun Karimi-Busheri and Dr. Aghdass Rasouli-Nia for their genuine support and advice. I also extend my thanks to the imaging facility, especially Geraldine Barron. Lastly, I take great pleasure to acknowledge my parents and my husband for always being there patiently by my side throughout this endeavour and for their immense love, moral support and persistent prayers which made this journey worthwhile. 1. iv 2. Table of Contents 1. Chapter I - Introduction ......................................................................................................... 1 1.1. Tumor Hypoxia ................................................................................................................ 2 1.1.1. Different types of tumor hypoxia ............................................................................... 2 1.1.2. Head and Neck Cancer............................................................................................... 5 1.1.3. Tumor hypoxia as a therapeutic barrier in HNC ........................................................ 6 1.1.3.1. Hypoxia induced radioresistance…………………………………………………6 1.1.3.2. Hypoxia induced chemoresistance………………………………………………..7 1.2. Cellular response to hypoxia at the molecular level ........................................................ 8 1.2.1. Hypoxia Inducible Factor dependent and independent mechanism……………….9 1.2.1.1. HIF-dependent mechanism…………………………………………………….....9 1.2.1.2. HIF-independent mechanism……………………………………………………11 1.3. Hypoxia responsive gene: Glucose transporter (GLUT) ............................................... 13 1.3.1. Regulation of glucose transport by hypoxia ............................................................ 17 1.4. Evaluation of hypoxia .................................................................................................... 18 1.4.1. Invasive and Non-invasive methods ........................................................................ 18 1.4.1.1. Invasive methods to assess tumor hypoxia………………………………………18 1.4.1.2. Non-invasive methods to assess tumor hypoxia………………………………....19 1.5. Radiosensitization of hypoxic cells ............................................................................... 21 1.5.1. Increase in oxygen delivery ..................................................................................... 21 1.5.2. Hypoxic cell radiosensitizers ................................................................................... 22 v 1.6. Hypoxic-cell cytotoxins ................................................................................................. 24 1.6.1. Different classes of bioreductive drugs.................................................................... 24 1.6.2. Drug of Interest: Tirapazamine (TPZ) ................................................................ ….28 1.6.2.1. Molecular mechanism of preferential toxicity………………………………….. 28 1.6.2.2. Early studies of TPZ……………………………………………………………..31 1.6.2.3. TPZ clinical trials and the setbacks……………………………………………..32 1.6.2.4. Recent advancements in TPZ studies…………………………………………..34 1.7. Research objectives ........................................................................................................ 36 2. Chapter II - Materials and Methods ..................................................................................... 40 2.1. Cell Culture .................................................................................................................... 41 2.2. Hypoxic condition .......................................................................................................... 41 2.3. Drug and/or chemical compounds ................................................................................. 41 2.4. Cytotoxicity assays ........................................................................................................ 42 2.4.1. MTT assay ............................................................................................................... 42 2.4.2. Crystal Violet Staining (CVS) assay........................................................................ 42 2.4.3. Colony formation assay ........................................................................................... 43 2.5. Western blot analysis ..................................................................................................... 43 2.6. Real-time reverse transcription polymerase chain reaction (Real-Time RT-PCR) ....... 44 2.7. Click Chemistry ............................................................................................................. 45 2.8. Affinity Purification assay ............................................................................................. 46 2.9. Statistical analysis…………………………………………………………………….....47 vi 3. Chapter III - Results ............................................................................................................. 48 3.1. Determination of optimum
Load more

Recommended publications
  • Method of Tumor Treatment
    Europaisches Patentamt J European Patent Office 0 Publication number: 0 649 658 A1 Office europeen des brevets EUROPEAN PATENT APPLICATION 0 Application number: 94202693.1 mt . ci .6 :A61K 31/53 0 Date of filing: 19.09.94 0 Priority: 22.09.93 US 125609 Palo Alto, CA 94304-1850 (US) 0 Date of publication of application: 0 Inventor: Brown, Martin J. 26.04.95 Bulletin 95/17 c/o Sterling Winthrop, Inc., 90 Park Avenue 0 Designated Contracting States: New York 10016 (US) AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE 0 Representative: Le Guen, Gerard 0 Applicant: THE BOARD OF TRUSTEES OF THE CABINET LAVOIX LELAND STANFORD JUNIOR UNIVERSITY 2, place d'Estienne d'Orves 900 Welch Road, Suite 350 F-75441 Paris Cedex 09 (FR) 0 Method of tumor treatment. 0 The present invention provides methods for increasing the cytotoxicity of a chemotherapy agent towards a solid tumor, such tumor susceptible to treatment with the chemotherapy agent, comprising administering to a mammal having such a tumor, from about one half hour to about twenty-four hours prior to administering the chemotherapy agent, or from about one hour to about two hours after administering the chemotherapy agent, a cytotoxicity-enhancing amount of a compound of Formula I. The invention also provides kits for treatment of such tumors which comprise a chemotherapy agent and a cytotoxicity-enhancing amount of a 1,2,4-ben- zotriazine oxide as defined in Formula I. The present invention also provides the use of a compound of Formula I capable of exerting a cytotoxic- enhancing effect on a cancer tumor for the manufacture of a medicament, for the therapeutic administration to a mammal having such a tumour from about one half hour to about twenty-four hours prior to treatment of said tumor with a chemotherapy agent.
    [Show full text]
  • Theranostics Self-Accelerating H2O2-Responsive Plasmonic
    Theranostics 2020, Vol. 10, Issue 19 8691 Ivyspring International Publisher Theranostics 2020; 10(19): 8691-8704. doi: 10.7150/thno.45392 Research Paper Self-accelerating H2O2-responsive Plasmonic Nanovesicles for Synergistic Chemo/starving therapy of Tumors Yao Tang1, Yuejia Ji1, Chenglin Yi2, Di Cheng1, Bin Wang1, Yun Fu1, Yufang Xu1, Xuhong Qian1, Yahya E. Choonara3, Viness Pillay3, Weiping Zhu1, Yunen Liu4 and Zhihong Nie2 1. State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China. 2. State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200438, China. 3. Department of Pharmacy and Pharmacology, University of the Witwatersrand, Parktown 2193 Johannesburg, South Africa. 4. Department of Emergency Medicine, the General Hospital of Northern Theater Command, Laboratory of Rescue Center of Severe Trauma PLA, Shenyang l10016, China. Corresponding author: E-mails: [email protected] (Z. Nie); [email protected] (Y. Liu); [email protected] (W. Zhu). © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.02.27; Accepted: 2020.06.17; Published: 2020.07.09 Abstract Rationale: Nanoscale vehicles responsive to abnormal variation in tumor environment are promising for use in targeted delivery of therapeutic drugs specifically to tumor sites. Herein, we report the design and fabrication of self-accelerating H2O2-responsive plasmonic gold nanovesicles (GVs) encapsulated with tirapazamine (TPZ) and glucose oxidase (GOx) for synergistic chemo/starving therapy of cancers.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0216288 A1 Chang (43) Pub
    US 20060216288A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0216288 A1 Chang (43) Pub. Date: Sep. 28, 2006 (54) COMBINATIONS FOR THE TREATMENT OF Publication Classification CANCER (51) Int. Cl. (75) Inventor: David Chang, Calabasas, CA (US) A 6LX 39/395 (2006.01) A6II 3/55 (2006.01) Correspondence Address: A6II 3 L/4545 (2006.01) SESS is 2-C A61K 31/4439 (2006.01) ONE AMGEN CENTERY DRIVE A6II 3/44 (2006.O1 ) THOUSAND OAKS, CA 91320-1799 (US) (52) U.S. Cl. ................... 424/143.1: 514/352: 514/210.2: (73) Assignee: Amgen Inc., Thousand Oaks, CA 514/318: 514/340; 514/217.04 (21) Appl. No.: 11/386,271 (22) Filed: Mar. 21, 2006 (57) ABSTRACT Related U.S. Application Data This invention is in the field of pharmaceutical agents and (60) Provisional application No. 60/664,381, filed on Mar. specifically relates to compounds, compositions, uses and 22, 2005. methods for treating cancer. Patent Application Publication Sep. 28, 2006 Sheet 1 of 5 US 2006/0216288A1 Figure 1 -- Vehicle X Compound B, 10 mpk 1800 -- Antibody A, 20 ug 1600 Compound B, 10 mpk+ 1400 Antibody A, 20 ug 1200 1000 800 600 p = 0.0003 1/10 1110 1/10 p < 0.0001 v v v v v v V 174. 22 27 32 37 42 47 Time (days) V Antibody A injection Patent Application Publication Sep. 28, 2006 Sheet 2 of 5 US 2006/0216288A1 Figure 2 -- Vehicle 1800 X Compound B, 75 mpk 1600 th- Antibody A, 500 u 1400 dy 9 1200 Compound B, 75 mpk+ Antibody A, 500 ug 1000 800 600 V Antibodyy A, ipp injectionin 400 200 p < 0.0001 st 0.9515 V.
    [Show full text]
  • Curriculum Vitae for Prof Søren M
    CURRICULUM VITÆ FOR PROFESSOR SØREN M. BENTZEN Full Name: Søren Møller Bentzen Title: Professor, Director of the Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, Director of the University of Maryland Greenebaum Comprehensive Cancer Center Biostatistics Shared Service, Director of the Biostatistics Core of the Institute of Clinical and Translational Research, and Director of Translational Research, Maryland Proton Therapy Alliance, University of Maryland School of Medicine Academic Credentials : M.Sc., Ph.D., D.M.Sc., F.A.S.T.R.O. Affiliations: Professor, tenured, Department of Epidemiology and Public Health, primary faculty appointment, University of Maryland School of Medicine, Baltimore, MD, USA Professor of Radiation Oncology, secondary faculty appointment, University of Maryland School of Medicine, Baltimore, MD, USA Director, Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA Director, University of Maryland Greenebaum Comprehensive Cancer Center Biostatistics Shared Service, University of Baltimore School of Medicine, Baltimore, MD, USA Director, Biostatistics Core, Institute for Clinical and Translational Research, University of Maryland Baltimore, Baltimore, MD, USA Director of Translational Research, Maryland Proton Alliance, University of Baltimore School of Medicine, Baltimore, MD, USA Member, University of Maryland Greenebaum Comprehensive Cancer Center, Experimental Therapeutics
    [Show full text]
  • The Role of Free Radicals in the Effectiveness of Anti-Cancer Chemotherapy in Hypoxic Ovarian Cells and Tumours Clifford Fong
    The role of free radicals in the effectiveness of anti-cancer chemotherapy in hypoxic ovarian cells and tumours Clifford Fong To cite this version: Clifford Fong. The role of free radicals in the effectiveness of anti-cancer chemotherapy in hypoxic ovar- ian cells and tumours. [Research Report] Eigenenergy, Adelaide, Australia. 2017. hal-01659879v2 HAL Id: hal-01659879 https://hal.archives-ouvertes.fr/hal-01659879v2 Submitted on 18 Feb 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. The role of free radicals in the effectiveness of anti-cancer chemotherapy in hypoxic ovarian cells and tumours Clifford W. Fong Eigenenergy, Adelaide, South Australia, Australia. Email: [email protected] Keywords: ovarian cancer; cytotoxicity; hypoxia; anoxia; normoxia; free radicals; electron affinity; Abstract It has been shown that strong linear relationships exist between the hypoxic and anoxic cytotoxicity ratios for the A2780 human ovarian cancer cell lines and the adiabatic electron affinity for 17 currently clinically used or subclinical anti-cancer drugs. A similar linear relationship is also found for the cytotoxicity ratios under normoxia, but the effect is the opposite to those found for anoxia and hypoxia.
    [Show full text]
  • In Human Non-Small-Cell Lung Cancer Cell Lines?
    British Journal of Cancer (1999) 81(7), 1127–1133 © 1999 Cancer Research Campaign Article no. bjoc.1999.0819 Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines? EC Chinje1, AV Patterson1, MP Saunders1, SD Lockyer1, AL Harris2 and IJ Stratford1 1Experimental Oncology Group, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, UK; 2ICRF Clinical Oncology Unit, University of Oxford, Churchill Hospital, Oxford, UK Summary The bioreductive drug tirapazamine (TPZ, SR 4233, WIN 59075) is a lead compound in a series of potent cytotoxins that selectively kill hypoxic rodent and human solid tumour cells in vitro and in vivo. Phases II and III trials have demonstrated its efficacy in combination with both fractionated radiotherapy and some chemotherapy. We have evaluated the generality of an enzyme-directed approach to TPZ toxicity by examining the importance of the one-electron reducing enzyme NADPH:cytochrome P450 reductase (P450R) in the metabolism and toxicity of this lead prodrug in a panel of seven human non-small-cell lung cancer cell lines. We relate our findings on TPZ sensitivity in these lung lines with our previously published results on TPZ sensitivity in six human breast cancer cell lines (Patterson et al (1995) Br J Cancer 72: 1144–1150) and with the sensitivity of all these cell types to eight unrelated cancer chemotherapeutic agents with diverse modes of action. Our results demonstrate that P450R plays a significant role in the activation of TPZ in this panel of lung lines, which is consistent with previous observations in a panel of breast cancer cell lines (Patterson et al (1995) Br J Cancer 72: 1144–1150; Patterson et al (1997) Br J Cancer 76: 1338–1347).
    [Show full text]
  • Recent Progress in Targeted Delivery Vectors Based on Biomimetic Nanoparticles
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN Recent progress in targeted delivery vectors based on biomimetic nanoparticles Li Chen1, Weiqi Hong 1, Wenyan Ren1, Ting Xu1,2, Zhiyong Qian1 and Zhiyao He 1,2 Over the past decades, great interest has been given to biomimetic nanoparticles (BNPs) since the rise of targeted drug delivery systems and biomimetic nanotechnology. Biological vectors including cell membranes, extracellular vesicles (EVs), and viruses are considered promising candidates for targeted delivery owing to their biocompatibility and biodegradability. BNPs, the integration of biological vectors and functional agents, are anticipated to load cargos or camouflage synthetic nanoparticles to achieve targeted delivery. Despite their excellent intrinsic properties, natural vectors are deliberately modified to endow multiple functions such as good permeability, improved loading capability, and high specificity. Through structural modification and transformation of the vectors, they are pervasively utilized as more effective vehicles that can deliver contrast agents, chemotherapy drugs, nucleic acids, and genes to target sites for refractory disease therapy. This review summarizes recent advances in targeted delivery vectors based on cell membranes, EVs, and viruses, highlighting the potential applications of BNPs in the fields of biomedical imaging and therapy industry, as well as discussing the possibility of clinical translation and exploitation trend of these BNPs. Signal Transduction and Targeted Therapy (2021) 6:225; https://doi.org/10.1038/s41392-021-00631-2 1234567890();,: INTRODUCTION and platelets19. As the functional limitation of single-cell type, the Even if the emergence of nanotechnology has posted alternative hybrid cell membranes incorporated with multi-functions of several therapeutic opportunities, new delivery challenges appear timely cell types are also involved in this category20.
    [Show full text]
  • The Gynecologic Oncology Group: 43 Years of Success
    The Gynecologic Oncology Group The Gynecologic Oncology Group: 43 Years of Success Philip J. DiSaia, MD ‐ Group Chair The Gynecologic Oncology Group The Gynecologic Oncology Group: 43 Years of Success Philip J. DiSaia, MD ‐ Group Chair Acknowledgements A special word of gratitude to Mr. Kevin Schnieder for his editorial efforts in the production of this monograph. Dedications This effort is dedicated to current GOG Group Chair and President, Dr. Philip J. DiSaia. Copyright © 2013 by the Gynecologic Oncology Group Gynecologic Oncology Group Mission Statement The Gynecologic Oncology Group is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of gynecologic malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, and distribution of results. Continuous evaluation of our processes is utlized in order to constantly improve the quality of patient care. Preface | Philip J. DiSaia, MD Chair Since 1970, the Gynecologic Oncology Group (GOG) has moved the members of the Group themselves and the support provided progressively into the lead position among clinical trial groups by both the NCI and our industry partners. studying gynecologic cancer. The results of multiple GOG study protocols have formed the basis of the standard of care for many We look forward to many more years of productivity and success- malignant gynecologic neoplasms. Additionally, the GOG has con- ful research into gynecologic malignant neoplasia as we affiliate tributed greatly to improvements in staging procedures, quality of with NSABP and RTOG to form the new NRG Oncology.
    [Show full text]
  • Investigating the Anti-Tumour Properties of Iraqi Propolis in Vitro and in Vivo
    Republic of Iraq Ministry of Higher Education and Scientific Research Al-Nahrain University, College of Science, Biotechnology Department Investigating the Anti-tumour Properties of Iraqi Propolis in vitro and in vivo A Dissertation Submitted to the College of Science / Al-Nahrain University as a partial fulfillment of the requirements for the Degree of Doctorate of Philosophy in Biotechnology By Ghassan Mohammad Sulaiman B.Sc. Biology/ University of Baghdad /1995 M.Sc. Biology/ University of Baghdad / 2002 Supervised by Dr. Khulood W.Al Sammarae Dr. Ali.H.Ad'hiah Professor Assist. Professor July 2010 Rajab 1431 ﺑﹺ ﺴ ﻢﹺ ﺍ ﻟ ﻠﹶّ ﻪ ﺍ ﻟ ﺮّ ﺣ ﻤ ﻦﹺ ﺍ ﻟ ﺮّ ﺣ ﻴ ﻢﹺ ﻭ ﺃﹶ ﻭ ﺣ ﻰ ﺭ ﺑ ﻚ ﺇﹺ ﻟﹶ ﻰ ﺍ ﻟ ﻨ ﺤ ﻞﹺ ﺃﹶ ﻥ ﺍ ﺗ ﺨ ﺬ ﻱ ﻣ ﻦ ﺍ ﻟﹾ ﺠﹺ ﺒ ﺎ ﻝﹺ ﺑ ﻴ ﻮ ﺗ ﺎ ﻭ ﻣ ﻦ ﺍ ﻟ ﺸ ﺠ ﺮﹺ ﻭ ﻣ ﻤ ﺎ ﻳ ﻌ ﺮﹺ ﺷ ﻮ ﻥﹶ (٦٨) ﺛﹸ ﻢ ﻛﹸ ﻠ ﻲ ﻣ ﻦ ﻛﹸ ﻞﱢ ﺍ ﻟ ﺜﱠ ﻤ ﺮ ﺍ ﺕ ﻓﹶ ﺎ ﺳ ﻠﹸ ﻜ ﻲ ﺳ ﺒ ﻞﹶ ﺭ ﺑ ﻚ ﺫﹸ ﻟﹸ ﻼﹰ ﻳ ﺨ ﺮ ﺝ ﻣ ﻦ ﺑ ﻄﹸ ﻮ ﻧﹺ ﻬ ﺎ ﺷ ﺮ ﺍ ﺏ ﻣ ﺨ ﺘ ﻠ ﻒ ﺃﹶ ﻟﹾ ﻮ ﺍ ﻧ ﻪ ﻓ ﻴ ﻪ ﺷ ﻔﹶ ﺎ ﺀ ﻟ ﻠ ﻨ ﺎ ﺱﹺ ﺇﹺ ﻥﱠ ﻓ ﻲ ﺫﹶ ﻟ ﻚ ﻵ ﻳ ﺔﹰ ﻟﱢ ﻘﹶ ﻮ ﻡﹴ ﻳ ﺘ ﻔﹶ ﻜﱠ ﺮ ﻭ ﻥﹶ (٦٩) ﺻﺪﻕ ﺍﷲ ﺍﻟﻌﻈﻴﻢ ﺳﻮﺭﺓ ﺍﻟﻨﺤﻞ In the name of God Most Gracious, Most Merciful (68) “And your Lord inspired the bees saying:”Take you habitations in the mountains and in the trees and what they erect.
    [Show full text]
  • 3-Amino-1,2,4-Benzotriazine 4-Oxide: Characterization of a New
    J. Org. Chem. 2001, 66, 107-114 107 3-Amino-1,2,4-benzotriazine 4-Oxide: Characterization of a New Metabolite Arising from Bioreductive Processing of the Antitumor Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine) Tarra Fuchs, Goutam Chowdhury, Charles L. Barnes, and Kent S. Gates* Departments of Chemistry and Biochemistry, University of MissourisColumbia, Columbia, Missouri 65211 [email protected] Received August 11, 2000 Tirapazamine (1) is a promising antitumor agent that selectively causes DNA damage in hypoxic tumor cells, following one-electron bioreductive activation. Surprisingly, after more than 10 years of study, the products arising from bioreductive metabolism of tirapazamine have not been completely characterized. The two previously characterized metabolites are 3-amino-1,2,4-benzo- triazine 1-oxide (3) and 3-amino-1,2,4-benzotriazine (5). In this work, 3-amino-1,2,4-benzotriazine 4-oxide (4) is identified for the first time as a product resulting from one-electron activation of the antitumor agent tirapazamine by the enzymes xanthine/xanthine oxidase and NADPH:cytochrome P450 oxidoreductase. As part of this work, the novel N-oxide (4) was unambiguously synthesized and characterized using NMR spectroscopy, UV-vis spectroscopy, LC/MS, and X-ray crystal- lography. Under conditions where the parent drug tirapazamine is enzymatically activated, the metabolite 4 is produced but readily undergoes further reduction to the benzotriazine (5). Thus, under circumstances where extensive reductive metabolism occurs, the yield of the 4-oxide (4) decreases. In contrast, the isomeric two-electron reduction product 3-amino-1,2,4-benzotriazine 1-oxide (3) does not readily undergo enzymatic reduction and, therefore, is found as a major bioreductive metabolite under all conditions.
    [Show full text]
  • Identification of P450 Oxidoreductase As a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs
    Published OnlineFirst August 21, 2015; DOI: 10.1158/0008-5472.CAN-15-1107 Cancer Therapeutics, Targets, and Chemical Biology Research Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs Francis W. Hunter1, Richard J. Young2,3, Zvi Shalev4, Ravi N. Vellanki4, Jingli Wang1, Yongchuan Gu1,5, Naveen Joshi1, Sreevalsan Sreebhavan1, Ilan Weinreb4, David P. Goldstein6, Jason Moffat7, Troy Ketela8, Kevin R. Brown8, Marianne Koritzinsky4,7,9, Benjamin Solomon2,3,10, Danny Rischin3,10, William R. Wilson1, and Bradly G. Wouters4,7,11,12 Abstract Hypoxia is a prevalent feature of many tumors contributing SN30000 in three different genetic backgrounds. No other to disease progression and treatment resistance, and therefore genes consistently modified SN30000 sensitivity, even within constitutes an attractive therapeutic target. Several hypoxia- a POR-negative background. Knockdown or genetic knockout activated prodrugs (HAP) have been developed, including of POR reduced SN30000 reductive metabolism and clono- the phase III candidate TH-302 (evofosfamide) and the pre- genic cell death and similarly reduced sensitivity to TH-302 clinical agent SN30000, which is an optimized analogue of the under hypoxia. A retrospective evaluation of head and neck well-studied HAP tirapazamine. Experience with this therapeu- squamous cell carcinomas showed heterogeneous POR expres- tic class highlights an urgent need to identify biomarkers of sion and suggested a possible relationship between human HAP sensitivity, including enzymes responsible for prodrug papillomavirus status and HAP sensitivity. Taken together, our activation during hypoxia. Using genome-scale shRNA screens study identifies POR as a potential predictive biomarker of and a high-representation library enriched for oxidoreductases, HAP sensitivity that should be explored during the clinical we identified the flavoprotein P450 (cytochrome) oxidoreduc- development of SN30000, TH-302, and other hypoxia-directed tase (POR) as the predominant determinant of sensitivity to agents.
    [Show full text]
  • Radiotherapy in Cancer Care: Facing the Global Challenge
    FACING THE GLOBAL CHALLENGE FACING RADIOTHERAPY IN CANCER CARE: This publication presents a comprehensive overview of the major topics and issues to be taken into consideration when planning and implementing radiotherapy services. It provides an introduction to the challenges associated with radiotherapy and its achievements as a cancer treatment modality around the world. Written with health care managers in mind, it contains data on the status of radiotherapy services around the world, established and novel technologies, social and economic factors, current issues and the role of international organizations. Dedicated chapters focus on proton therapy, carbon ion radiotherapy, intraoperative radiotherapy, radiotherapy for children, HIV/AIDS related malignancies, and costing and quality management issues. RADIOTHERAPY IN CANCER CARE: FACING THE GLOBAL CHALLENGE Edited by: Eduardo Rosenblatt Eduardo Zubizarreta INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA ISBN 978–92–0–115013–4 @ RADIOTHERAPY IN CANCER CARE: FACING THE GLOBAL CHALLENGE The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GEORGIA OMAN ALBANIA GERMANY PAKISTAN ALGERIA GHANA PALAU ANGOLA GREECE PANAMA ANTIGUA AND BARBUDA GUATEMALA PAPUA NEW GUINEA ARGENTINA GUYANA PARAGUAY ARMENIA HAITI PERU AUSTRALIA HOLY SEE PHILIPPINES AUSTRIA HONDURAS POLAND AZERBAIJAN HUNGARY PORTUGAL BAHAMAS ICELAND QATAR BAHRAIN INDIA REPUBLIC OF MOLDOVA BANGLADESH INDONESIA ROMANIA BARBADOS IRAN, ISLAMIC REPUBLIC OF RUSSIAN FEDERATION BELARUS IRAQ RWANDA BELGIUM IRELAND
    [Show full text]